The mechanism of CTO1681 may allow it to reduce the production of a broad range of proinflammatory cytokines in DLBCL.
Jordan Gauthier, MD, MSc
Advertisement
Articles by Jordan Gauthier, MD, MSc
Advertisement
Latest Updated Articles
How Might CTO1681 Prevent CRS After CAR T-Cell Therapy in DLBCL?December 15th 2025
Advertisement
Advertisement
Trending on CancerNetwork
1
Current Treatment Landscape of HER2-Positive Metastatic Breast Cancer and Phase 3 Trial Overview
2
The Moonlight Shift: Dr Joshua Richter on Myeloma, Myths, and the C-Word
3
FDA Approves Afami-cel in Metastatic Synovial Sarcoma
4
Zanzalintinib/Atezolizumab Misses Survival End Point in Non-MSI-H mCRC Subgroup
5